Objective endpoint and recruitment layer for CNS biotechs licensing clinical assets and racing to prove signal in noisy trials.

1. Capital is moving into CNS startups that begin with clinical-stage assets, increasing demand for execution tooling immediately after a license deal closes.
2. The ability to assemble pipelines from licensed assets compresses timelines, so sponsors need trial-readiness infrastructure earlier than traditional discovery-stage biotechs.
3. Schizophrenia, tinnitus, and epilepsy-related studies are all difficult to measure consistently, making objective and remote outcome capture more valuable.
4. Investors are already backing veteran teams in this category, which means trial execution is becoming the new source of differentiation for emerging CNS companies.

Catalyst. Tortugas' $106M launch around four licensed clinical-stage CNS assets shows that more capital will be deployed into programs where execution speed and cleaner trial signal determine whether the asset is worth advancing.

The company provides a CNS trial signal layer that combines pre-screening workflows, remote symptom capture, wearable or smartphone-based behavioral endpoints, and site scorecards tailored to each protocol. It plugs into the sponsor's CRO and existing eCOA setup rather than replacing them, making adoption feasible for lean biotech teams. The first product package helps sponsors identify higher-probability patients, reduce protocol deviations, and generate cleaner interim reads in schizophrenia and tinnitus studies. Over time, the platform accumulates cross-trial neuro-outcome data that improves enrollment targeting and endpoint selection for future programs.

What's different. Most clinical trial software is indication-agnostic and most CROs optimize for operational throughput, not for extracting clean signal from messy neuro endpoints. This startup wins by specializing narrowly in CNS proof-of-concept studies, building protocol-specific workflows, patient phenotyping logic, and indication-level benchmark data that get better with every study. That creates both a workflow moat and a proprietary neuro-outcomes dataset moat.

Jobs to be done

flowchart LR
  Buyer[CMO at CNS biotech] --> Pain[Noisy enrollment and subjective CNS endpoints]
  Pain --> Product[CNS trial signal layer]
  Product --> Outcome[Faster enrollment and cleaner Phase II readouts]

Executive takeaways

• CNS trial signal quality is a real, expensive bottleneck because placebo response, baseline inflation, and subjective measures can erase apparent treatment effects before Phase II decisions are made.
• The proposed wedge fits a live buyer segment: newly funded, asset-led CNS biotechs that must operationalize clinical-stage programs quickly with lean internal teams.
• The market is crowded with capable incumbents, but most are either broad eClinical suites or narrow endpoint tools rather than a CNS-specific overlay spanning screening, endpoints, and site performance.
• Adoption tailwinds are tangible: eCOA budgets are scaling, implementation timelines are compressing, and sponsors increasingly want workflow-compatible overlays rather than rip-and-replace systems.
• Compliance is a gating factor. Privacy approvals, IRB/EC review, and emerging AI guidance mean a startup must look validation-first from day one.
• The initial beachhead is strategically credible but economically narrow; venture upside depends on expanding from one-study overlays into repeatable neuro data and portfolio workflows.

Market definition

This market is the workflow and data layer used by sponsors running noisy CNS trials to improve patient screening, endpoint capture, data quality, and site oversight without replacing the CRO or core eClinical stack. Buyers are emerging biopharma and venture-backed CNS sponsors, primarily in North America and Europe. It excludes full-service CRO outsourcing, discovery platforms, and generic EDC by itself.

Customer and buyer

The initial user is the lean clinical development team preparing a newly licensed CNS asset for proof-of-concept execution. The economic buyer is usually the CMO or VP Clinical Operations, with input from biometrics, digital/endpoint specialists, and the CRO study team. Budget most likely comes from study startup, recruitment, and endpoint-instrumentation lines rather than a standalone platform budget.

Buying triggers

• A CNS asset is newly licensed and the sponsor must finalize protocol instrumentation, screening logic, and sites before first-patient-in. [1][8][11]
• The study design is vulnerable to placebo response, rating variability, or baseline score inflation. [3][4][28]
• The sponsor needs faster implementation and lower dependence on service-heavy eCOA builds. [8][9][12]

Willingness to pay

Public list pricing is rare, but incumbent messaging repeatedly sells on faster startup, lower operational burden, better enrollment, and cleaner data. That implies willingness to pay when the product is framed as study-risk reduction rather than net-new platform replacement. [6][8][12][24]

Category dynamics

Growth signal ~14% digital-biomarkers CAGR and accelerating eCOA enterprise adoption

Validation signals

• Tortugas launched with $106M and a multi-asset clinical CNS pipeline, indicating fresh study demand in exactly the proposed buyer segment.
• Medable reported 80% revenue growth from portfolio-level eCOA adoption, suggesting buyers are scaling beyond one-off pilots.
• Signant cut eCOA implementation timelines by 30%, confirming startup speed is a live buyer priority.
• Koneksa reached database lock on a Parkinson’s digital-measure study, signaling continued sponsor investment in validation of remote neuro measures.
• Signant is acquiring Ametris, indicating strategic value in combining eClinical workflows with digital measures.
• Medable/CVS and Medable partner-network announcements show distribution through sites, retail, and CRO channels is increasingly important.

Regulatory & technical constraints

• Digital measures need clear analytical and clinical validation, not just sensor data collection.
• Remote participant data requires strong sponsor and PI oversight, with traceable review workflows.
• Regional privacy rules such as CNIL expectations in France/EU and China PIPL can alter deployment design.
• Interoperability with incumbent eCOA/CRO/site systems is required to avoid workflow rejection.

Priority competitors split into broad eClinical incumbents (Signant, Clario, Medable), digital-biomarker specialists (Koneksa, Ametris), and neuro-assessment specialists (Cogstate). The startup’s opening depends on being more CNS-specific than the suites and more workflow-complete than the point solutions.

Why incumbents do not win by default

• Broad eClinical platforms. Signant, Clario, and Medable are strong on validation, libraries, and global delivery, but they optimize for horizontal deployment across studies and indications; a purpose-built CNS overlay can still win where signal extraction matters more than suite breadth.
• CROs. CROs remain the default operator, but incumbent vendors now explicitly build CRO-compatible partner motions, implying room for overlays that slot into existing execution rather than replace it.
• Digital biomarker specialists. Koneksa and Ametris are strong on algorithms, devices, and objective data, but they do not obviously solve full recruitment, screening orchestration, and site-ops needs for lean CNS sponsors.
• Cognitive assessment point solutions. Cogstate is credible in schizophrenia cognition and remote assessment, but it is primarily an endpoint module plus services wrapper rather than a broader protocol-linked signal layer.

This company should be built as a CNS trial signal layer for newly funded biotechs that license clinical-stage neuro assets and need faster, cleaner Phase II proof. The immediate buyer is the CMO or VP Clinical Operations at a 2-5 asset CNS biotech with a lean team that must lock sites, screening logic, and endpoint instrumentation before first-patient-in. The initial product should not replace the CRO or core eCOA stack; it should sit on top of them as a protocol-linked overlay for patient pre-screening, remote symptom capture, site scorecards, and interim signal-quality monitoring. The best first wedge is schizophrenia proof-of-concept studies in the U.S. and Europe because the pain is acute, the study volume is more credible than tinnitus alone, and the buying trigger is tied to a specific study-start event. Research supports that noisy CNS endpoints, placebo response, and baseline inflation create real buyer pain, but it does not yet prove that sponsors will buy a separate overlay once the CRO and eCOA vendor are chosen. The company can win if it proves measurable operational ROI first, such as lower screen-fail rates and faster enrollment, then compounds into a cross-trial CNS dataset that improves protocol design and site selection. The strategic risk is that the beachhead is economically narrow and incumbents keep compressing implementation timelines, so expansion into broader neuro portfolio workflows must be earned rather than assumed. This is a credible company to build, but the board-level question is whether early pilots produce budget pull strong enough to justify an independent product category.

Problem

• CNS Phase II studies often fail to show clear efficacy because subjective endpoints, placebo response, baseline inflation, and site variability drown out real signal.
• Newly funded asset-led CNS biotechs inherit clinical-stage programs but still run them with lean teams, generic eCOA tools, CRO-heavy workflows, and manual screening.
• Sponsors can burn tens of millions on a noisy study before they know whether the asset failed biologically or the trial failed operationally.

Solution

• Provide a CRO-compatible overlay for protocol-specific patient pre-screening, remote symptom capture, behavioral endpoint collection, and site-performance monitoring.
• Package the first product around one live study so the sponsor can improve enrollment quality, reduce protocol deviations, and monitor signal reliability before interim readouts.
• Build a longitudinal CNS study dataset across screening, adherence, endpoint variability, and site behavior that improves future protocol and portfolio decisions.

Why we win

• The product is specialized around noisy CNS proof-of-concept studies rather than generic trial infrastructure, which matches the actual pain buyers describe.
• The buying trigger is concrete because budget appears when a newly licensed asset is preparing for study startup, not as a speculative software purchase.
• An overlay model fits how sponsors already buy through CRO and study startup budgets, reducing adoption friction versus a rip-and-replace platform.
• If early deployments capture repeatable data on screening quality, endpoint variance, and site performance, the company compounds into a disease-specific workflow and data moat.

Milestones

flowchart LR
  Wedge[Schizophrenia Phase II wedge] --> MVP[CRO-compatible signal layer MVP]
  MVP --> Proof[Lower screen fails cleaner interim reads]
  Proof --> Expansion[Multi-study neuro trial intelligence platform]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least half of interviewed CMOs and VP Clinical Ops rank signal quality or enrollment quality as a top-three Phase II risk worth buying software against.
• At least 3 of the first 10 serious target accounts agree to a paid pilot before first-patient-in rather than asking for a free design partnership.
• The first 5 paid studies improve screened-to-randomized conversion by at least 15% versus each sponsor's prior baseline or plan assumption.
• At least 2 early customers convert from paid pilot to full-study contract while keeping the CRO and core eCOA vendor in place.
• At least 30% of early customers expand to a second study or adjacent indication within 12 months of the first deployment.

Open diligence questions

• Will a CMO fund this as a separate overlay once the CRO and eCOA vendor are already contracted?
• Which KPI creates the fastest budget pull, faster enrollment, lower screen-fail rate, better adherence, or lower endpoint variance?
• Is schizophrenia the right first wedge, or does a less crowded indication provide faster paid proof despite lower study volume?
• How much implementation and QA burden will incumbent vendors impose on an overlay that touches endpoint workflows?
• Can the company retain enough structured data rights to build a moat without triggering sponsor privacy or IP objections?

Model sanity

• Revenue engine. Base-case revenue is driven by 3 paid studies in Y1 growing to 7 active studies by Q4Y3 at a blended $330K annual contract value.
• Must go right. The company has to win budget before first-patient-in and convert at least 2 early pilots into full-study contracts, or the Y2 study ramp breaks.
• Model breaks if. A one-quarter slip in sales cycle or a drop to 68% gross margin removes roughly $240K of cash and pushes the pre-seed cushion close to the downside low point.
• Next-round proof. The next financing is justified if the company reaches 8-12 cumulative paying study contracts with repeatable schizophrenia KPI proof and a clear second-indication expansion path.

Scenarios

Sensitivity

flowchart LR
  LicensedAssets --> StudyStart
  StudyStart --> OverlaySale
  OverlaySale --> ActiveStudies
  ActiveStudies --> Revenue
  Revenue --> GrossProfit
  GrossProfit --> Cash

Flags: The model assumes buyers fund a standalone overlay before first-patient-in even when CRO and eCOA vendors are already selected; the BP explicitly says this still needs live proof. · Revenue is concentrated in a small number of studies, so one delayed sponsor start can move quarterly revenue by roughly $80K-$140K. · Y3 is still slightly EBITDA-negative, which means the next round must be earned with KPI proof and repeatability, not with profitability.

• Slow biotech sales cycles. Small CNS biotechs may delay new tooling purchases until financing closes and protocols are locked. Mitigation: Sell at the asset-transition moment with a lightweight overlay that fits inside existing CRO budgets and timelines.
• Insufficient clinical differentiation. If the platform does not clearly improve enrollment quality or endpoint reliability, sponsors will default to incumbents. Mitigation: Start with one or two indications, run tightly scoped pilots, and publish sponsor-level benchmarks on measurable operational gains.
• Regulatory and data quality complexity. Remote neuro endpoint capture can create validation, compliance, and acceptance challenges in regulated studies. Mitigation: Limit initial claims to operational decision support, integrate with validated trial systems, and build quality documentation from day one.